These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

182 related articles for article (PubMed ID: 27936965)

  • 1. AVP-786 for the treatment of agitation in dementia of the Alzheimer's type.
    Garay RP; Grossberg GT
    Expert Opin Investig Drugs; 2017 Jan; 26(1):121-132. PubMed ID: 27936965
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effect of Dextromethorphan-Quinidine on Agitation in Patients With Alzheimer Disease Dementia: A Randomized Clinical Trial.
    Cummings JL; Lyketsos CG; Peskind ER; Porsteinsson AP; Mintzer JE; Scharre DW; De La Gandara JE; Agronin M; Davis CS; Nguyen U; Shin P; Tariot PN; Siffert J
    JAMA; 2015 Sep 22-29; 314(12):1242-54. PubMed ID: 26393847
    [TBL] [Abstract][Full Text] [Related]  

  • 3. AVP-786 as a promising treatment option for Alzheimer's Disease including agitation.
    Khoury R; Marx C; Mirgati S; Velury D; Chakkamparambil B; Grossberg GT
    Expert Opin Pharmacother; 2021 May; 22(7):783-795. PubMed ID: 33615952
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Investigational drugs for treating agitation in persons with dementia.
    Garay RP; Citrome L; Grossberg GT; Cavero I; Llorca PM
    Expert Opin Investig Drugs; 2016 Aug; 25(8):973-83. PubMed ID: 27232589
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Advancements in the treatment of agitation in Alzheimer's disease.
    Antonsdottir IM; Smith J; Keltz M; Porsteinsson AP
    Expert Opin Pharmacother; 2015; 16(11):1649-56. PubMed ID: 26159445
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Progresses in treating agitation: a major clinical challenge in Alzheimer's disease.
    Panza F; Solfrizzi V; Seripa D; Imbimbo BP; Santamato A; Lozupone M; Prete C; Greco A; Pilotto A; Logroscino G
    Expert Opin Pharmacother; 2015; 16(17):2581-8. PubMed ID: 26389682
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Dextromethorphan and quinidine are suitable for off-label short-term treatment of agitation in people with Alzheimer's disease following first-line non-drug approaches.
    Corbett A; Ballard C
    Evid Based Med; 2016 Feb; 21(1):25. PubMed ID: 26701197
    [No Abstract]   [Full Text] [Related]  

  • 8. Pharmacological treatments for alleviating agitation in dementia: a systematic review and network meta-analysis.
    Kongpakwattana K; Sawangjit R; Tawankanjanachot I; Bell JS; Hilmer SN; Chaiyakunapruk N
    Br J Clin Pharmacol; 2018 Jul; 84(7):1445-1456. PubMed ID: 29637593
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Dextromethorphan and Quinidine for Treating Agitation in Patients With Alzheimer Disease Dementia.
    Ballard C; Sharp S; Corbett A
    JAMA; 2015 Sep 22-29; 314(12):1233-5. PubMed ID: 26393843
    [No Abstract]   [Full Text] [Related]  

  • 10. AVP-923, a combination of dextromethorphan hydrobromide and quinidine sulfate for the treatment of pseudobulbar affect and neuropathic pain.
    Olney N; Rosen H
    IDrugs; 2010 Apr; 13(4):254-65. PubMed ID: 20373255
    [TBL] [Abstract][Full Text] [Related]  

  • 11. An update on the advancements in the treatment of agitation in Alzheimer's disease.
    Porsteinsson AP; Antonsdottir IM
    Expert Opin Pharmacother; 2017 Apr; 18(6):611-620. PubMed ID: 28300462
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Dextromethorphan-Quinidine for Agitation in Alzheimer Disease.
    Newman JC; Steinman MA
    JAMA; 2016 Mar; 315(11):1166. PubMed ID: 26978214
    [No Abstract]   [Full Text] [Related]  

  • 13. Dextromethorphan-Quinidine for Agitation in Alzheimer Disease--Reply.
    Cummings JL; Siffert J
    JAMA; 2016 Mar; 315(11):1166-7. PubMed ID: 26978215
    [No Abstract]   [Full Text] [Related]  

  • 14. Combination drug shows promise for treating agitation in patients with Alzheimer's disease.
    Wise J
    BMJ; 2015 Sep; 351():h5015. PubMed ID: 26400972
    [No Abstract]   [Full Text] [Related]  

  • 15. Dextromethorphan/quinidine: AVP 923, dextromethorphan/cytochrome P450-2D6 inhibitor, quinidine/dextromethorphan.
    Drugs R D; 2005; 6(3):174-7. PubMed ID: 15869321
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A 2023 update on the advancements in the treatment of agitation in Alzheimer's disease.
    Lee D; Clark ED; Antonsdottir IM; Porsteinsson AP
    Expert Opin Pharmacother; 2023 Apr; 24(6):691-703. PubMed ID: 36958727
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Dextromethorphan/quinidine: a review of its use in adults with pseudobulbar affect.
    Yang LP; Deeks ED
    Drugs; 2015 Jan; 75(1):83-90. PubMed ID: 25420446
    [TBL] [Abstract][Full Text] [Related]  

  • 18. AXS-05: an investigational treatment for Alzheimer's disease-associated agitation.
    Ward K; Citrome L
    Expert Opin Investig Drugs; 2022 Aug; 31(8):773-780. PubMed ID: 35763451
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Evidence for using dextromethorphan-quinidine for the treatment of agitation in dementia.
    Tampi RR; Joshi P; Marpuri P; Tampi DJ
    World J Psychiatry; 2020 Apr; 10(4):29-33. PubMed ID: 32399396
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Dextromethorphan/quinidine for the treatment of pseudobulbar affect.
    Patatanian E; Casselman J
    Consult Pharm; 2014 Apr; 29(4):264-9. PubMed ID: 24704895
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.